Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CombinatoRx, Incorporated
CombinatoRx Publishes Data on Selective Amplification of Synergistic Combination Drug Candidate
February 14th, 2009
CombinatoRx, Incorporated (Nasdaq: CRXX) announced the publication of new in vivo research in Arthritis Research and Therapy on a systems biology based strategy that selectively amplifies the anti-inflammatory activity of very low dose glucocorticoids in immune cells without modulation of pathways associated with glucocorticoid toxicity. This research, which was conducted by CombinatoRx scientists, demonstrates that the multi-target mechanism of low dose prednisolone (a glucocorticoid) combined with dipyridamole (a cardiovascular agent) creates a dissociated activity profile with an increased therapeutic window through selective amplification of glucocorticoid-mediated anti-inflammatory...
Source: Law & Health Weekly (2009-02-14)
|
|
Advertisement |
|
|
|
